{
    "organizations": [],
    "uuid": "39079232fe1a6ef30cfbcd14f4a880e0ebbbf202",
    "author": "",
    "url": "https://www.reuters.com/article/brief-concert-pharmaceuticals-completes/brief-concert-pharmaceuticals-completes-enrollment-in-phase-2a-trial-of-ctp-543-in-alopecia-areata-idUSASC09X97",
    "ord_in_thread": 0,
    "title": "BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Concert Pharmaceuticals Inc:\n* CONCERT PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 2A TRIAL OF CTP-543 IN ALOPECIA AREATA\n* CONCERT PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG COHORTS OF PHASE 2A TRIAL IN Q4 OF 2018\n* CONCERT PHARMACEUTICALS INC - PHASE 2B CLINICAL TRIAL EVALUATING CTP-543 IS EXPECTED TO BEGIN IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T14:09:00.000+03:00",
    "crawled": "2018-04-25T14:24:48.023+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "concert",
        "pharmaceutical",
        "inc",
        "concert",
        "pharmaceutical",
        "completes",
        "enrollment",
        "phase",
        "2a",
        "trial",
        "alopecia",
        "areata",
        "concert",
        "pharmaceutical",
        "inc",
        "expects",
        "report",
        "topline",
        "data",
        "mg",
        "mg",
        "cohort",
        "phase",
        "2a",
        "trial",
        "q4",
        "concert",
        "pharmaceutical",
        "inc",
        "phase",
        "2b",
        "clinical",
        "trial",
        "evaluating",
        "expected",
        "begin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}